Displaying drugs 6851 - 6875 of 8178 in total
Niobium
Niobium has been used in trials studying the treatment of Obesity and Overweight.
Investigational
Matched Description: … Niobium has been used in trials studying the treatment of Obesity and Overweight. …
CP-195543
CP-195,543 has been used in trials studying the treatment of Arthritis, Rheumatoid.
Investigational
Matched Description: … CP-195,543 has been used in trials studying the treatment of Arthritis, Rheumatoid. …
PF-03814735
PF-03814735 has been used in trials studying the treatment of Solid Tumors.
Investigational
Matched Description: … PF-03814735 has been used in trials studying the treatment of Solid Tumors. …
CEP-37440
CEP-37440 has been used in trials studying the treatment of Solid Tumors.
Investigational
Matched Description: … CEP-37440 has been used in trials studying the treatment of Solid Tumors. …
ME-344
ME-344 has been used in trials studying the treatment of Solid Tumors.
Investigational
Matched Description: … ME-344 has been used in trials studying the treatment of Solid Tumors. …
AZD-0424
AZD0424 has been used in trials studying the treatment of Advanced Solid Tumours.
Investigational
Matched Description: … AZD0424 has been used in trials studying the treatment of Advanced Solid Tumours. …
CT-2584
CT-2584 has been used in trials studying the treatment of Prostate Cancer.
Investigational
Matched Description: … CT-2584 has been used in trials studying the treatment of Prostate Cancer. …
Hydroxypropyl tetrahydropyrantriol
Hydroxypropyl tetrahydropyrantriol has been used in trials studying the basic science of Aging.
Investigational
Matched Description: … Hydroxypropyl tetrahydropyrantriol has been used in trials studying the basic science of Aging. …
Troxerutin
Troxerutin has been used in trials studying the treatment of Chronic Venous Insufficiency.
Investigational
Matched Description: … Troxerutin has been used in trials studying the treatment of Chronic Venous Insufficiency. …
AGN-201904
Agn 201904 has been used in trials studying the prevention of Peptic Ulcer.
Investigational
Matched Description: … Agn 201904 has been used in trials studying the prevention of Peptic Ulcer. …
JQ1
First-in-class potent and selective inhibitor of the BRD4 signaling pathway.
Investigational
Matched Description: … First-in-class potent and selective inhibitor of the BRD4 signaling pathway.[A252967] …
ASP-7317
ASP-7317 consists of human embryonic stem cell-derived retinal pigment epithelium cells.
Investigational
Matched Description: … ASP-7317 consists of human embryonic stem cell-derived retinal pigment epithelium cells. …
CLZ-2002
CLZ-2002 consists of allogeneic mesenchymal stem cells derived neuronal regeneration-promoting cells.
Investigational
Matched Description: … CLZ-2002 consists of allogeneic mesenchymal stem cells derived neuronal regeneration-promoting cells. …
Sitamaquine
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis.
Investigational
Matched Description: … Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of …
GI-4000
A vaccine containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant and antitumor activity.
Investigational
Matched Description: … containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of …
EGEN-001
EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity.
Investigational
Matched Description: … EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin …
BMS-564929
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
Matched Description: … So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. …
Fluoromisonidazole F-18
Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer).
Investigational
Matched Description: … Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission …
CX-2009
CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).
Investigational
Matched Description: … investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of …
OT-730
OT-730 is under investigation in clinical trial NCT00753168 (Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma).
Investigational
Matched Description: … OT-730 is under investigation in clinical trial NCT00753168 (Phase 1-2 Evaluation of OT-730 Eye Drops …
Tovinontrine
Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor. Tovinontrine is under investigation in clinical trial NCT04474314 (A Study of IMR-687 in Subjects With Sickle Cell Disease).
Investigational
Matched Description: … Tovinontrine is under investigation in clinical trial NCT04474314 (A Study of IMR-687 in Subjects With …
TBX-3400
TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.[L44281,L44286]
Investigational
Matched Description: … TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear …
DCVAC/OvCa
DCVAC/OvCa is a therapy comprising autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo. It is under investigation for the treatment of ovarian cancer.
Investigational
Matched Description: … It is under investigation for the treatment of ovarian cancer. …
Zilebesiran
Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)).
Investigational
Matched Description: … Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of …
9,10-Deepithio-9,10-Didehydroacanthifolicin
A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. (Thromb Res 1992;67(4):345-54 & Cancer Res 1993;53(2):239-41)
Experimental
Matched Description: … A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. …
Displaying drugs 6851 - 6875 of 8178 in total